NOVARTIS UK LIMITED

What NOVARTIS UK LIMITED does

Novartis UK Limited (legally Novartis Pharmaceuticals UK Limited) is the wholly-owned UK subsidiary of Swiss-headquartered Novartis AG (NYSE: NVS), operating from registered offices at The WestWorks Building, White City Place, London. Established in 1996, the company employs between 1,001 and 5,000 staff and operates as a for-profit pharmaceutical commercial entity with no separate venture funding history, as its R&D and capital structure sit at the parent group level.

The company supplies a broad portfolio of prescription medicines across nine major therapy areas: cardio-metabolic (ENTRESTO, LEQVIO), dermatology (COSENTYX, XOLAIR), haematology (FABHALTA, JAKAVI, SCEMBLIX), immunology (ILARIS), neuroscience (AIMOVIG, KESIMPTA), oncology (KISQALI, TAFINLAR+MEKINIST, SANDOSTATIN LAR), radioligand therapy (LUTATHERA, Pluvicto), respiratory/inflammation, and rheumatology. Its proprietary radioligand therapy platform, combining disease-targeting ligands with therapeutic radionuclides, represents a differentiated precision oncology modality. The company supports healthcare professionals through the Novartis Pro portal, a centralised digital hub providing product information, formulary support, training, events, and clinical resources.

Novartis UK generates revenue through the sale of prescription pharmaceuticals to NHS hospitals, trusts, clinical commissioning groups, Integrated Care Systems, and dispensing pharmacies via field-based medical science liaisons and key account managers. Distribution is exclusively routed through the NHS and regulated healthcare channels; the company does not sell direct to consumers, and pricing is governed by confidential NHS reimbursement agreements and MHRA/EMA regulatory approvals. Customer engagement extends beyond prescribers to NHS system-level decision-makers via collaborative working programmes and health inequalities initiatives, with additional partnership activity through the Pathway Bond programme with Imperial College London and Hammersmith & Fulham Council.

Name

NOVARTIS UK LIMITED

Legal name

Novartis Pharmaceuticals UK Limited

Website

https://novartis.co.uk

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Novartis UK Limited is the UK subsidiary of Novartis AG, supplying prescription pharmaceuticals across nine therapy areas — including oncology, radioligand therapy, cardio-metabolic, and neuroscience — exclusively to the NHS and regulated UK healthcare channels, supporting HCPs through the Novartis Pro portal.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

Keywords

• Prescription pharmaceuticals
• Radioligand therapy
• Oncology medicines
• Cardio-metabolic treatments
• Biopharmaceutical products

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Novartis generates revenue through the sale of prescription pharmaceutical medicines across therapy areas including cardio-metabolic, dermatology, haematology, immunology, neuroscience, oncology, radioligand therapy, respiratory, and rheumatology. Products are supplied to NHS hospitals, clinicians, and healthcare systems in the UK.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Novartis UK discovers, develops, and supplies innovative prescription pharmaceutical medicines across nine therapy areas: cardio-metabolic, dermatology, haematology, immunology, neuroscience, oncology, radioligand therapy, respiratory/inflammation, and rheumatology. Products such as ENTRESTO, LEQVIO, COSENTYX, XOLAIR, FABHALTA, JAKAVI, SCEMBLIX, ILARIS, AIMOVIG, KESIMPTA, KISQALI, TAFINLAR+MEKINIST, SANDOSTATIN LAR, LUTATHERA, and Pluvicto are supplied to NHS hospitals, clinicians, and UK healthcare systems, supported by the Novartis Pro healthcare professional portal.

Product overview

Novartis UK operates as a pharmaceutical company offering a broad portfolio of prescription medicines across multiple therapy areas. The product portfolio includes treatments for cardio-metabolic conditions (ENTRESTO, LEQVIO), dermatology (COSENTYX, XOLAIR), haematology (FABHALTA, JAKAVI, SCEMBLIX), immunology (ILARIS), neuroscience (AIMOVIG, KESIMPTA), oncology (KISQALI, TAFINLAR+MEKINIST, SANDOSTATIN LAR), radioligand therapy (LUTATHERA, Pluvicto), respiratory and inflammation (XOLAIR), and rheumatology (COSENTYX). These products are supported through the Novartis Pro Portal, a healthcare professional platform providing product information, resources, training materials, and formulary support. The company does not offer a unified platform-plus-modules architecture but rather distributes individual branded pharmaceutical products supplemented by a professional information portal.

Differentiator

Problem solved

Functional benefit

Products and services

• ENTRESTO (sacubitril/valsartan) Cardio-metabolic prescription medicine used for heart failure treatment. Distributed to NHS hospitals, clinicians, and UK healthcare systems.
• LEQVIO (inclisiran) siRNA-based cardio-metabolic prescription medicine for cholesterol management in hypercholesterolaemia. Distributed via NHS and regulated healthcare channels.
• COSENTYX (secukinumab) IL-17 inhibitor prescription medicine for psoriasis, ankylosing spondylitis, and other rheumatology/dermatology inflammatory conditions. Distributed via NHS hospitals and clinical settings.
• XOLAIR (omalizumab) Anti-IgE prescription medicine used in dermatology, respiratory and inflammation conditions including asthma and chronic urticaria. Distributed through NHS and regulated channels.
• FABHALTA (iptacopan) Haematology prescription medicine (complement inhibitor) for rare blood disorders. Distributed via NHS haematology centres and prescribing specialists.
• JAKAVI (ruxolitinib) JAK inhibitor prescription medicine for myelofibrosis and polycythaemia vera. Distributed via NHS haematology settings.
• SCEMBLIX (asciminib) STAMP inhibitor prescription medicine for chronic myeloid leukaemia (CML). Distributed through NHS haematology specialist centres.
• ILARIS (canakinumab) Anti-IL-1β monoclonal antibody prescription medicine for autoinflammatory diseases. Distributed via NHS immunology and specialist prescribing channels.
• AIMOVIG (erenumab) CGRP receptor antagonist prescription medicine for migraine prevention. Distributed via NHS neurology and specialist headache services.
• KESIMPTA (ofatumumab) Anti-CD20 monoclonal antibody prescription medicine for multiple sclerosis. Distributed via NHS neurology specialist prescribing.
• KISQALI (ribociclib) CDK4/6 inhibitor prescription medicine for breast cancer treatment. Distributed via NHS oncology specialist centres.
• TAFINLAR (dabrafenib) + MEKINIST (trametinib) BRAF/MEK inhibitor combination prescription therapy for non-small cell lung cancer (NSCLC) and melanoma. Distributed via NHS oncology specialist prescribing.
• SANDOSTATIN LAR (octreotide acetate) Somatostatin analogue prescription medicine for neuroendocrine tumours. Distributed via NHS oncology and specialist endocrinology centres.
• LUTATHERA (lutetium [177Lu] oxodotreotide) Proprietary radioligand therapy (RLT) for neuroendocrine tumours, combining the radionuclide lutetium-177 with a somatostatin-receptor-targeting ligand. Distributed via NHS specialist nuclear medicine and oncology centres.
• Pluvicto (lutetium [177Lu] vipivotide tetraxetan) Proprietary radioligand therapy (RLT) for metastatic castration-resistant prostate cancer, combining lutetium-177 with a PSMA-targeting ligand. Distributed via NHS specialist nuclear medicine and oncology centres.
• Novartis Pro Portal Gated centralised digital hub for UK healthcare professionals providing product information, clinical resources, training materials, events, webinars, and formulary/service support across all Novartis therapy areas.

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Imperial College LondoncoreStrategic or Co-development PartnerImperial College London is a key academic partner in the Hammersmith & Fulham Pathway Bond initiative. The partnership connects students with work placement opportunities at biotech firms and major employers including Novartis, leveraging the university's research and educational resources to create pathways to employment for young Londoners facing AI-driven job displacement.
• Hammersmith & Fulham CouncilcoreStrategic or Co-development PartnerHammersmith & Fulham Council is the convening authority for the Pathway Bond initiative. The council uses its convening power to unite business (including Novartis), education (Imperial College London), and community stakeholders to create employment pathways for young people. Novartis participates by providing work placements as part of the programme targeting students like Ely.
• Patient GroupscoreStrategic or Co-development PartnerNovartis UK has a dedicated Patient Group Partnership programme that positions patients at the heart of everything the company does. The programme focuses on collaborative partnerships with patient advocacy organisations to improve outcomes for patients and their communities, covering unmet needs across multiple therapy areas.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• Bayer UK: Bayer's UK pharmaceutical operations market branded specialty products in cardiology, women's health, and oncology via comparable NHS channels, with overlapping cardiovascular and radiology-adjacent presence relevant to Novartis's cardiology and radioligand franchises.
• Sanofi UK: Sanofi UK's branded pharmaceutical portfolio spans immunology (Dupixent competitor to COSENTYX), rare disease, vaccines, and diabetes, marketed via comparable NHS-facing commercial teams and competing directly in several of Novartis's core therapy areas.
• Roche UK: Roche Products (UK) markets branded oncology, ophthalmology, and diagnostics-adjacent therapeutics through NHS channels with comparable scale and a directly overlapping oncology portfolio that competes with KISQALI, TAFINLAR+MEKINIST, and radioligand offerings.
• Takeda UK: Takeda's UK subsidiary markets branded specialty pharmaceuticals across rare disease, oncology, neuroscience, and gastroenterology through NHS channels, with overlapping presence in haematology, oncology, and neuroscience therapy areas where Novartis UK also operates.
• Merck Sharp & Dohme (MSD) UK: MSD's UK subsidiary markets a broad branded pharma portfolio with particularly strong oncology overlap (competing immuno-oncology assets), vaccines, and specialty medicines via the same NHS enterprise sales and market access infrastructure.
• Eli Lilly UK: Eli Lilly's UK subsidiary markets a broad branded pharma portfolio with notable oncology, diabetes, and immunology overlap, using the same NHS commercial and market access model and competing directly with several Novartis assets including in migraine and oncology.
• Boehringer Ingelheim UK: Boehringer Ingelheim's UK subsidiary operates a branded pharma business focused on respiratory, cardiovascular, and specialty therapies with comparable NHS commercial infrastructure, directly competing with XOLAIR, OFEV-adjacent assets, and ENTRESTO in cardiology.
• AstraZeneca UK: AstraZeneca's UK subsidiary markets an overlapping branded pharmaceutical portfolio across oncology, cardiovascular, respiratory, and rare disease with comparable NHS-facing commercial model and NHS formulary access priorities. It is the closest direct peer given similar UK scale and breadth.
• Pfizer UK: Pfizer's UK subsidiary operates a broad branded pharma portfolio across oncology, vaccines, inflammation/immunology, and rare disease with the same NHS distribution model and similar headcount scale, directly competing for NHS formulary positions across multiple Novartis therapy areas.
• GSK UK: GSK's UK operations market branded specialty pharmaceuticals, vaccines, and HIV medicines via the same NHS channels with overlapping therapy-area presence in respiratory and immunology, and a comparable enterprise sales motion targeting HCPs and NHS decision-makers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/novartisuk

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NOVARTIS UK LIMITED